Business
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK’s B7-H3 Antibody Drug Conjugate (ADC)
MIAMI, January 12, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK", LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC).
About this update from Gsk Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":292,"url":"https://media.zenfs.com/en/business-wire.com/223c3132f8de14a774f9f06b2d8b69c0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CqJ_U0TtCxdt5JqU4oo33A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/223c3132f8de14a774f9f06b2d8b69c0","width":480,"height":292}},"lazy":false},{"type":"text","content":"Summit to Advance Development Opportunities of Ivonescimab with GSK’s Novel B7-H3 risvutatug rezetecan","length":102,"tagName":"p","attribs":{}},{"type":"text","content":"Multiple Solid Tumor Settings to Be Pursued with Clinical Trials Expected to Start in Mid-2026","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"MIAMI, January 12, 2026--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc ("GSK", LSE/NYSE: GSK) to evaluate ivonescimab, a novel, investigational PD-1 / VEGF bispecific antibody, in combination with risvutatug rezetecan (also known as GSK’227), GSK’s novel investigational B7-H3 targeting antibody drug conjugate (ADC), across multiple solid tumor settings, including small cell lung cancer (SCLC).","length":497,"tagName":"p"},{"type":"text","content":""We believe exploring new mechanisms and combinations with the potential to surpass current options for patients and physicians will have the most profound impact on those battling the toughest cancer challenges today," stated Robert W. Duggan and Dr. Maky Zanganeh, Co-Chief Executive Officers of Summit. "With the goal of accelerating development of ivonescimab in multiple solid tumors, this collaboration enables us to swiftly advance ivonescimab and expand Summit’s combination strategy."","length":513,"tagName":"p"},{"type":"text","content":"The intent of this agreement is to investigate the combination potential of ivonescimab and risvutatug rezetecan in multiple solid tumor environments to determine the safety profile and potential anti-tumor effects.","length":215,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Summit will supply ivonescimab for the planned study, while GSK will manage the day-to-day clinical oper...